We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.'s share was trading at $47.69 as of February 16th. HROW’s trailing and forward P/E were 9.64 and 44.25 respectively according to Yahoo Finance.
[caption id="attachment_536361" align="aligncenter" width="750"]Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. HROW...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.